Skip to content

Cannabis: all studies

Page 254 of 287: studies 2,531 to 2,540 of 2,868, newest first. Back to the cannabis overview

Research

Intoxications by the dissociative new psychoactive substances diphenidine and methoxphenidine

Clinical Toxicology May 8, 2015 Anders Helander, O. Beck, Matilda Bäckberg

BACKGROUND: Diphenidine (1-(1,2-diphenylethyl)piperidine) and its 2-methoxylated derivative methoxphenidine (MXP, 2-MeO-diphenidine) are substances with dissociative effects that were recently introduced for "recreational" purpose through the online-based sale of new psychoactive substances (NPS). A number of analytically confirmed non-fatal intoxications associated with diphenidine or MXP have...

fNIRS suggests increased effort during executive access in ecstasy polydrug users.

Psychopharmacology May 2015 C A Roberts, C Montgomery

Ecstasy use is associated with cognitive impairment, believed to result from damage to 5-HT axons. Neuroimaging techniques to investigate executive dysfunction in ecstasy users provide a more sensitive measure of cognitive impairment than behavioural indicators. The present study assessed executive access to semantic memory in ecstasy polydrug users and non-users. Twenty ecstasy polydrug users...

5-Meo-DALT-induced Cyclic Myoclonus (P3.013)

Neurology April 6, 2015 Thananan Thammongkolchai, Pichet Termsarasab, Ayham Alkhachroum et al. 43 citations

Objective: To report the first case of myoclonus as neurologic presentation of 5-MeO-DALT abuse Background: 5-Meo-DALT (N,N-diallyl-5-methoxytryptamine) is a relatively new hallucinogen, initially sold online in 2004. It is a psychedelic compound from the tryptamine family which affects monoamine neurotransmitters including dopamine and serotonin. It is a psychostimulant with strong visual...

Soma, an Enigmatic, Mysterious Plant of the Vedic Āryas: An Appraisal

Revista de Fomento Social March 4, 2015 Niranjan Chandra Shah 10 citations

Soma plant has been a mystery since a long time.A number of plants were proposed as Soma in the past by various authorities.Wasson (1968) proposed and claimed with a specific approach that Amanita muscaria, a mushroom was the Soma of the gveda.The juice of it was used as Soma drink.The Vedic Āryas (earlier called 'Vedic Āryans'), were the composer of gveda.They used to compose hymns (mantras)...

Consumption of Cocaine Once – Trigger of Psychosis in a Consumer Hashish – Clinical Case

European Psychiatry March 1, 2015 Mariana Pinheiro, J. Pais, T. Cabral

The consumption of cannabinoids has increased exponentially in the young. The cannabis-induced psychotic disorder is a rare condition, with transient paranoid ideation being the most common manifestation. Symptoms of anxiety are the most common adverse reaction associated with the moderate use of smoked cannabis. Cocaine use, in turn, is related to the appearance of delusions and hallucinations...

The effects of beta-arrestin1 deletion on acute cannabinoid activity, brain cannabinoid receptors and tolerance to cannabinoids in mice.

Journal of receptor and signal transduction research February 2015 Chris S Breivogel, Manan S Vaghela

Previous studies have indicated a role for beta-arrestin2 in the regulation of brain cannabinoid effects and cannabinoid CB1 receptors, but whether beta-arrestin1 has a role has not been investigated. To determine the role of beta-arrestin1 in cannabinoid activity. Beta-arrestin1 -/- mice and their wild-type (+/+) counterparts were assayed for antinociceptive and temperature-decreasing effects...

DOI: 10.3109/10799893.2014.1003659 (opens in new tab) Full text (opens in new tab) Cp55940 G-protein Antinociception Delta-9-tetrahydrocannabinol +1

Illegal Drugs Laws: Clearing a 50-Year-Old Obstacle to Research

PLoS Biology January 27, 2015 David Nutt 66 citations

The United Nations drug control conventions of 1960 and 1971 and later additions have inadvertently resulted in perhaps the greatest restrictions of medical and life sciences research. These conventions now need to be revised to allow neuroscience to progress unimpeded and to assist in the innovation of treatments for brain disorders. In the meantime, local changes, such as the United Kingdom...

DOI: 10.1371/journal.pbio.1002047 (opens in new tab) Clearing Schedule Obstacle Medical research

Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signalling

Swiss Medical Weekly January 11, 2015 Matthias E. Liechti 188 citations

Novel psychoactive substances are newly used designer drugs ("internet drugs", "research chemicals", "legal highs") potentially posing similar health risks to classic illicit substances. Chemically, many novel psychoactive substances can be classified as phenethylamines, amphetamines, synthetic cathinones, piperazines, pipradrols/piperidines, aminoindanes benzofurans, and tryptamines....

DOI: 10.4414/smw.2015.14043 (opens in new tab) Serotonin Pharmacology Designer drug Monoamine neurotransmitter +1

Neues von der anderen Seite

2015 Paul-Philipp Hanske, Benedikt Sarreiter

Ende der siebziger Jahre zeigte sich Albert Hofmann schwer enttäuscht vom Schicksal der von ihm entdeckten »Wunderdroge«: LSD – mein Sorgenkind lautete der Titel des damals erschienenen Erinnerungsbuchs. Hatte man die Substanz noch in den sechziger Jahren als Königsweg zur Erkundung der Psyche gefeiert, folgte bald der Rückschlag: Halluzinogene wurden flächendeckend verboten, ein Effekt des...

Hallucinogens causing seizures? A case report of the synthetic amphetamine 2,5-dimethoxy-4-chloroamphetamine.

The Neurohospitalist January 2015 Mark J Burish, Katie L Thoren, Maura Madou et al.

Although traditional hallucinogenic drugs such as marijuana and lysergic acid diethylamide (LSD) are not typically associated with seizures, newer synthetic hallucinogenic drugs can provoke seizures. Here, we report the unexpected consequences of taking a street-bought hallucinogenic drug thought to be LSD. Our patient presented with hallucinations and agitation progressing to status...

DOI: 10.1177/1941874414528939 (opens in new tab) Full text (opens in new tab) Epilepsy Neurochemistry Neuropharmacology Neurotoxicity syndromes +2